PubRank

John Kurhanewicz

Author PubWeight™ 160.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008 4.79
2 Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med 2013 4.23
3 Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med 2007 4.13
4 Double spin-echo sequence for rapid spectroscopic imaging of hyperpolarized 13C. J Magn Reson 2007 3.35
5 Compressed sensing for resolution enhancement of hyperpolarized 13C flyback 3D-MRSI. J Magn Reson 2008 2.39
6 Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice. J Magn Reson 2009 2.05
7 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 2011 2.05
8 Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 2006 2.04
9 Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004 1.98
10 Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol 2010 1.97
11 3D compressed sensing for highly accelerated hyperpolarized (13)C MRSI with in vivo applications to transgenic mouse models of cancer. Magn Reson Med 2010 1.92
12 Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003 1.89
13 Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. J Magn Reson 2010 1.84
14 Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 2010 1.81
15 Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 2004 1.69
16 Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 2008 1.69
17 Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002 1.68
18 Fast dynamic 3D MR spectroscopic imaging with compressed sensing and multiband excitation pulses for hyperpolarized 13C studies. Magn Reson Med 2010 1.67
19 Investigation of tumor hyperpolarized [1-13C]-pyruvate dynamics using time-resolved multiband RF excitation echo-planar MRSI. Magn Reson Med 2010 1.64
20 Feasibility of using hyperpolarized [1-13C]lactate as a substrate for in vivo metabolic 13C MRSI studies. Magn Reson Imaging 2008 1.64
21 Pulse sequence for dynamic volumetric imaging of hyperpolarized metabolic products. J Magn Reson 2008 1.64
22 Multiband excitation pulses for hyperpolarized 13C dynamic chemical-shift imaging. J Magn Reson 2008 1.62
23 Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007 1.61
24 In vivo carbon-13 dynamic MRS and MRSI of normal and fasted rat liver with hyperpolarized 13C-pyruvate. Mol Imaging Biol 2009 1.61
25 Monitoring urea transport in rat kidney in vivo using hyperpolarized ¹³C magnetic resonance imaging. Am J Physiol Renal Physiol 2012 1.60
26 Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 2008 1.60
27 Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004 1.58
28 A novel application of 1H magnetic resonance spectroscopy: non-invasive identification of spermatogenesis in men with non-obstructive azoospermia. Hum Reprod 2010 1.56
29 Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer 2004 1.55
30 Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. Proc Natl Acad Sci U S A 2011 1.52
31 Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009 1.48
32 Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume. Radiology 2011 1.44
33 Hyperpolarized [2-13C]-fructose: a hemiketal DNP substrate for in vivo metabolic imaging. J Am Chem Soc 2009 1.38
34 Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2011 1.37
35 Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004 1.36
36 Metabolic imaging in the anesthetized rat brain using hyperpolarized [1-13C] pyruvate and [1-13C] ethyl pyruvate. Magn Reson Med 2010 1.34
37 Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 2003 1.31
38 Registration of MR prostate images with biomechanical modeling and nonlinear parameter estimation. Med Phys 2006 1.30
39 Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology 2007 1.29
40 Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005 1.27
41 Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med 2008 1.25
42 Imaging of blood flow using hyperpolarized [(13)C]urea in preclinical cancer models. J Magn Reson Imaging 2011 1.23
43 Analysis of hyperpolarized dynamic 13C lactate imaging in a transgenic mouse model of prostate cancer. Magn Reson Imaging 2009 1.21
44 Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging 2008 1.21
45 Multi-kernel graph embedding for detection, Gleason grading of prostate cancer via MRI/MRS. Med Image Anal 2012 1.20
46 Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004 1.19
47 Hyperpolarized (13)C spectroscopy and an NMR-compatible bioreactor system for the investigation of real-time cellular metabolism. Magn Reson Med 2010 1.18
48 Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003 1.18
49 Evaluation of the ERETIC method as an improved quantitative reference for 1H HR-MAS spectroscopy of prostate tissue. Magn Reson Med 2009 1.18
50 Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010 1.18
51 Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005 1.17
52 A hydrogen peroxide-responsive hyperpolarized 13C MRI contrast agent. J Am Chem Soc 2011 1.15
53 Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate 2013 1.15
54 Generation of hyperpolarized substrates by secondary labeling with [1,1-13C] acetic anhydride. Proc Natl Acad Sci U S A 2009 1.15
55 Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas. Cancer Res 2012 1.13
56 Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004 1.10
57 In vivo hyperpolarized 13C MR spectroscopic imaging with 1H decoupling. J Magn Reson 2008 1.08
58 Characterization of intervertebral disc degeneration by high-resolution magic angle spinning (HR-MAS) spectroscopy. Magn Reson Med 2005 1.08
59 Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed 2009 1.05
60 Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008 1.05
61 Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed 2006 1.05
62 High resolution (13)C MRI with hyperpolarized urea: in vivo T(2) mapping and (15)N labeling effects. IEEE Trans Med Imaging 2013 1.05
63 High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 2006 1.04
64 Rapid sequential injections of hyperpolarized [1-¹³C]pyruvate in vivo using a sub-kelvin, multi-sample DNP polarizer. Magn Reson Imaging 2012 1.03
65 Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am J Roentgenol 2010 1.02
66 Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 2010 1.01
67 Improved signal to noise in high-resolution magic angle spinning total correlation spectroscopy studies of prostate tissues using rotor-synchronized adiabatic pulses. Magn Reson Med 2005 1.01
68 Use of hyperpolarized [1-13C]pyruvate and [2-13C]pyruvate to probe the effects of the anticancer agent dichloroacetate on mitochondrial metabolism in vivo in the normal rat. Magn Reson Imaging 2012 1.00
69 Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 2012 1.00
70 Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? Radiology 2008 1.00
71 Semi-parametric time-domain quantification of HR-MAS data from prostate tissue. NMR Biomed 2010 1.00
72 Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience. Radiology 2008 0.99
73 Simultaneous multiagent hyperpolarized (13)C perfusion imaging. Magn Reson Med 2013 0.99
74 Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012 0.99
75 Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions. Radiology 2006 0.98
76 High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging 2007 0.98
77 T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol 2009 0.97
78 Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features. AJR Am J Roentgenol 2009 0.96
79 Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol 2006 0.95
80 Combined parallel and partial fourier MR reconstruction for accelerated 8-channel hyperpolarized carbon-13 in vivo magnetic resonance Spectroscopic imaging (MRSI). J Magn Reson Imaging 2013 0.95
81 Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience. J Magn Reson Imaging 2013 0.95
82 The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int 2013 0.94
83 Quantitative measurement of cancer metabolism using stimulated echo hyperpolarized carbon-13 MRS. Magn Reson Med 2013 0.94
84 Expandable and rigid endorectal coils for prostate MRI: impact on prostate distortion and rigid image registration. Med Phys 2005 0.94
85 A method for simultaneous echo planar imaging of hyperpolarized ¹³C pyruvate and ¹³C lactate. J Magn Reson 2012 0.93
86 Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2007 0.93
87 Lactic acid and proteoglycans as metabolic markers for discogenic back pain. Spine (Phila Pa 1976) 2008 0.93
88 Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int 2007 0.92
89 Correlation of HR-MAS spectroscopy derived metabolite concentrations with collagen and proteoglycan levels and Thompson grade in the degenerative disc. Spine (Phila Pa 1976) 2005 0.92
90 Frequency-specific SSFP for hyperpolarized ¹³C metabolic imaging at 14.1 T. Magn Reson Imaging 2012 0.92
91 A magnetic resonance spectroscopy driven initialization scheme for active shape model based prostate segmentation. Med Image Anal 2010 0.92
92 Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET. J Nucl Med 2013 0.91
93 Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2004 0.91
94 A clinical comparison of rigid and inflatable endorectal-coil probes for MRI and 3D MR spectroscopic imaging (MRSI) of the prostate. J Magn Reson Imaging 2008 0.91
95 In vivo measurement of normal rat intracellular pyruvate and lactate levels after injection of hyperpolarized [1-(13)C]alanine. Magn Reson Imaging 2011 0.91
96 Spectral embedding based probabilistic boosting tree (ScEPTre): classifying high dimensional heterogeneous biomedical data. Med Image Comput Comput Assist Interv 2009 0.90
97 Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate. Magn Reson Med 2009 0.90
98 Generating super stimulated-echoes in MRI and their application to hyperpolarized C-13 diffusion metabolic imaging. IEEE Trans Med Imaging 2011 0.90
99 Diffusion MR of hyperpolarized 13C molecules in solution. Analyst 2013 0.90
100 Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model. Cancer Biol Ther 2011 0.90
101 Semi supervised multi kernel (SeSMiK) graph embedding: identifying aggressive prostate cancer via magnetic resonance imaging and spectroscopy. Med Image Comput Comput Assist Interv 2010 0.89
102 Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI. Radiother Oncol 2008 0.87
103 Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer. J Magn Reson Imaging 2012 0.87
104 Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A 2012 0.86
105 Post-processing correction of the endorectal coil reception effects in MR spectroscopic imaging of the prostate. J Magn Reson Imaging 2010 0.86
106 High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience. Radiology 2006 0.86
107 Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J Endourol 2008 0.85
108 Diagnostic tools and imaging methods in intervertebral disk degeneration. Orthop Clin North Am 2011 0.85
109 High-resolution magic angle spinning NMR spectroscopy of human osteoarthritic cartilage. NMR Biomed 2011 0.84
110 Generating contrast in hyperpolarized 13C MRI using ligand-receptor interactions. Analyst 2012 0.83
111 Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev 2012 0.83
112 Assessment of intervertebral disc degeneration with magnetic resonance single-voxel spectroscopy. Magn Reson Med 2009 0.83
113 Feasibility of magnetic resonance spectroscopy for evaluating fetal lung maturity. J Pediatr Surg 2006 0.82
114 Calculation of gestational age in late second and third trimesters by ex vivo magnetic resonance spectroscopy of amniotic fluid. Am J Obstet Gynecol 2010 0.81
115 Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score. Eur Radiol 2006 0.81
116 Toward adaptive stereotactic robotic brachytherapy for prostate cancer: demonstration of an adaptive workflow incorporating inverse planning and an MR stealth robot. Minim Invasive Ther Allied Technol 2010 0.81
117 Quantitative metabolic profiles of 2nd and 3rd trimester human amniotic fluid using (1)H HR-MAS spectroscopy. MAGMA 2009 0.81
118 (1)H HR-MAS spectroscopy for quantitative measurement of choline concentration in amniotic fluid as a marker of fetal lung maturity: inter- and intraobserver reproducibility study. J Magn Reson Imaging 2008 0.79
119 Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy. J Magn Reson Imaging 2013 0.79
120 Application of Good's buffers to pH imaging using hyperpolarized (13)C MRI. Chem Commun (Camb) 2015 0.78
121 Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. AJR Am J Roentgenol 2011 0.78
122 Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates. J Magn Reson Imaging 2013 0.78
123 Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 2006 0.78
124 Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance. Abdom Imaging 2014 0.77
125 Perfusion and diffusion sensitive 13C stimulated-echo MRSI for metabolic imaging of cancer. Magn Reson Imaging 2012 0.77
126 Progress in prostate cancer imaging. Urol Oncol 2012 0.77
127 A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer. BJU Int 2011 0.76
128 Interactive, multi-modality image registrations for combined MRI/MRSI-planned HDR prostate brachytherapy. J Contemp Brachytherapy 2011 0.76
129 Correlating high-resolution magic angle spinning NMR spectroscopy and gene analysis in osteoarthritic cartilage. NMR Biomed 2015 0.75
130 Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy. Radiother Oncol 2013 0.75
131 Endorectal MRI after radiation therapy: questioning the sextant analysis. J Magn Reson Imaging 2011 0.75
132 Local staging of prostate cancer: comparative accuracy of T2-weighted endorectal MR imaging and transrectal ultrasound. Clin Imaging 2012 0.75
133 Magnetic resonance spectroscopic imaging of benign prostatic tissue: findings at 3.0 T compared to 1.5 T-initial experience. Clin Imaging 2011 0.75
134 In vivo (1)H magnetic resonance spectroscopy of amniotic fluid and fetal lung at 1.5 T: technical challenges. J Magn Reson Imaging 2008 0.75
135 Image registration for prostate MR spectroscopy using modeling and optimization of force and stiffness parameters. Conf Proc IEEE Eng Med Biol Soc 2004 0.75